Time to revise myeloma diagnostic criteria? A decade of accumulated evidence on a serum free light chain ratio of ≥100
Abstract
ABSTRACT: In 2014, the International Myeloma Working Group (IMWG) expanded multiple myeloma diagnostic criteria to include a serum free light chain (sFLC) ratio of ≥100 as a standalone myeloma-defining biomarker, based on studies suggesting ∼80% risk of progression to overt myeloma at 2 years. However, subsequent studies demonstrate a substantially lower risk of progression, with population-based registry data showing a 2-year risk as low as 30.4% in this group. Importantly, subsequent data showed that >70% of patients with an sFLC ratio ≥100 have 24-hour monoclonal proteinuria
Fields of Study & Subjects
Multiple Myeloma Research and Treatments
Multiple and Secondary Primary Cancers
Cancer Treatment and Pharmacology
Publication details
- Journal / source
- Blood
- Publisher
- American Society of Hematology
- Volume
- 147
- Issue
- 13
- Pages
- 1412–1415
- Publication date
- 20 January 2026
- Language
- EN